Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373542 · ClinicalTrials.gov registry record · Phase 4
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
A Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT00373542 is a Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS) that has completed, run by GlaxoSmithKline. The registered enrollment target is 39 participants, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00373542, a Phase 4 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
Conditions Studied
Interventions
- DRUG ropinirole CR-RLS
Study Locations (20)
Florida
- GSK Investigational Site - Brandon
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - St. Petersburg
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Austell
- GSK Investigational Site - Macon
Alabama
- GSK Investigational Site - Jasper
- GSK Investigational Site - Tuscaloosa
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - San Diego
Colorado
- GSK Investigational Site - Greenwood
- GSK Investigational Site - Wheat Ridge
Illinois
- GSK Investigational Site - Elk Grove Village
- GSK Investigational Site - Normal
Kansas
- GSK Investigational Site - Lenexa
- GSK Investigational Site - Topeka
Arizona
- GSK Investigational Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373542
The ClinicalTrials.gov registry entry for NCT00373542 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (59% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ropinirole CR-RLS is the first listed.
NCT00373542 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT00373542 about?
NCT00373542 is a clinical study titled "12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome". The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
What is the current status of trial NCT00373542?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2006-10. Estimated completion is 2007-06.
What conditions does trial NCT00373542 study?
This clinical trial studies the following conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS).
What interventions are being tested in trial NCT00373542?
The interventions under investigation include: ropinirole CR-RLS (DRUG).
Who is sponsoring clinical trial NCT00373542?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373542 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.